Inside Innovation

Microsoft and its Seattle-based neighbor Adaptive Biotechnologies have been in partnership since 2018 on immuno-sequencing advancements. Now, they’re pivoting their work to collaborate on COVID-19

Adaptive Biotechnologies received FDA clearance for the clonoSEQ® Assay, used to assess the minimal residual disease in a chronic lymphocytic leukemia patient’s blood. Previously, the

Boston-based biotech startup GentiBio has secured licensing deals with Seattle Children’s Research Institute and Benaroya Research Institute at Virginia Mason. The technology from both Seattle-based

Adaptive Biotechnologies is continuing with its plans to move into a 100,000-square-foot headquarters. The new facility, slated to open next year, will allow Adaptive to

Cellular therapy company Lyell Immunopharma is investing $50 million in a new 70,000 square foot manufacturing facility located in Bothell, Washington. This investment will support

CorneaGen, a Seattle-based provider of corneal transplant tissue, committed to donating $100,000 to help fund corneal transplant surgeries for underprivileged people of color in need

The University of Washington and Seattle-based HDT Bio Corp. announced the development of a promising COVID-19 vaccine candidate that uses a cutting-edge approach. Based on

Seattle-based biotech research startup A-Alpha Bio has received an $800,000 grant from the Bill & Melinda Gates Foundation that will support drug research for treating

“I think the most important thing in building a company and the thing that we want inside Sana is finding a mission that will change

Seattle Genetics and Genmab, a Danish biotechnology company, announced a 24% response rate for their joint cervical cancer medication tisotumab vedotin, paving the way for

Sana Biotechnology, a Seattle-based company developing cell and gene therapies, announced it has raised more than $700 million to aid in the discovery and development

Bothell, Washington’s Ventec Life Systems partnered with General Motors to rapidly scale their ventilator manufacturing capabilities during the onset of COVID-19. They are on track